FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-47 | Systemic ozone treatment in chronic migraine: a focus on disability reduction and medication use Sergio Sorrenti,1,2 Matteo Ciuffreda,1 Emanuele Pisello,1 Luca Brugiaferri,2 Azzurra Federici,2 Cristiano Piangatelli,3 Dario Galante4 | 1U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 2Scuola di Specializzazione in Anestesia Rianimazione, Terapia Intensiva e del Dolore, UNIVPM, Ancona, Italy; 3Direttore U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 4Direttore U.O.C. Anestesia e Rianimazione, Cerignola (FG), Italy
221 -
PO-74 | Effectiveness of auricular acupuncture in the management of menstrual migraine: a pilot study Sergio Sorrenti,1,2 Matteo Ciuffreda,1 Emanuele Pisello,1 Luca Brugiaferri,2 Azzurra Federici,2 Cristiano Piangatelli,3 Dario Galante4 | 1U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 2Scuola di Specializzazione in Anestesia Rianimazione, Terapia Intensiva e del Dolore, UNIVPM, Ancona, Italy; 3Direttore U.O.C. Anestesia Rianimazione Terapia del Dolore, AST Ancona, Fabriano (AN), Italy; 4Direttore U.O.C. Anestesia e Rianimazione, Cerignola (FG), Italy
374 -
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
183 -
PO-60 | Effectiveness of aerobic exercise, Mulligan technique, and myofascial release in migraine management: preliminary data from a randomized controlled trial Marco Bravi,1,2 Fabio Santacaterina,1,2 Federica Bressi,1,2 Francesca Nasto,1,2 Claudia Altamura,1,2 Fabrizio Vernieri1,2 | 1Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Rome, Italy; 2Università Campus Bio-Medico di Roma, Rome, Italy
139 -
PO-42 | OnaBotulinumtoxin-A in chronic migraine patients with short or long disease history and psychiatric comorbidities: preliminary data from an Italian multicentric study (the BACH Study) Fabrizio Vernieri,1,2 Marilena Marcosano,2 Licia Grazzi,3 Danilo Antonio Montisano,3 Raffaele Ornello,4 Simona Sacco,4 Chiara Rosignoli,4 Alberto Doretti,5 Maria Albanese,6 Giovanna Viticchi,7 Nicoletta Brunelli, Luigi d’Onofrio,2 Luisa Fofi,1 Claudia Altamura,1,2 Patrizio Pasqualetti8 | 1Fondazione Policlinico Campus Bio-Medico, Roma, Italy; 2Università Campus Bio-Medico di Roma, Italy; 3Istituto Neurologico Besta, Milano, Italy; 4Università degli Studi l’Aquila, Italy; 5Istituto Auxologico, Milano, Italy; 6Policlinico Tor Vergata, Roma, Italy; 7Università Politecnica Marche, Italy; 8Sapienza Università di Roma, Italy
201 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
374 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
244 -
Expert consensus document on criteria for assessing disability and invalidity in chronic primary headache. From the law to the implementation of diagnostic-therapeutic pathways Editors: Cristina Tassorelli, Giorgio Sandrini, Cherubino Di Lorenzo, Rosa Maria Gaudio, Lara Merighi, Elena Ruiz de la Torre
171PDF: 107 -
PO-49 | Distress perception and mutuality in caregivers of migraine patients with depressive symptoms.: baseline evaluation of the observational prospective real-life MiDEAR study to evaluate the effectiveness of fremanezumab for reducing the caregivers’ burden a C. Altamura,1 L. Fofi,1 R. Ornello,2 G. Ceccardi,3 C. Aurilia,4 A. Montisano,5 I. Orologio,6 D. Mascarella,7 G. Viticchi,8 M. Marcosano,1 N. Brunelli,1 G. Del Mastro,1 A. Onofri,2 A. Lanfranchi,3 G. Fiorentini,4 M. Silvestro,6 V. Favoni,7 G. Egeo,4 M. Silvestrini,8 M. Peresson,9 S. Cevoli,7 A. Russo,6 R. Rao,3 L. Grazzi,5 S. Sacco,2 F. Vernieri1 | 1Fondazione Policlinico Universitario Campus Bio-Medico, Rome; 2University of L'Aquila, L’Aquila; 3ASST Spedali Civili di Brescia, Brescia; 4IRCCS San Raffaele, Rome; 5IRCCS Fondazione istituto Neurologico Carlo Besta, Milan; 7IRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna; 6University of Campania; Caserta; 8Marche Polytechnic University, Ancona; 9San Pietro Fatebenefratelli Hospital, Rome, Italy
103 -
PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine Laura Marino,1 Marta Lioi1, Rosario Iannacchero,2 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
315 -
PO-04 | Mindfulness-based behavioral intervention for adolescents with high-frequency primary headaches: feasibility of a prospective multicenter study Beatrice Baldo,1 Giulia De Lorenzi,1 Valeria Marletta,1 Ilaria Bonemazzi,1 Alessia Raffagnato,2 Cristina Vassia,3 Emanuela Serri,3 Antonella Versace,4 Daniela D’Agnano,4 Vittorio Sciruicchio,4 Licia Grazzi,5 Irene Toldo1 | 1Juvenile Headache Center, Department of Woman’s and Child’s Health, University of Padua; 2Child and Adolescent Neuropsychiatric Unit, Department of Women's and Children's Health, University of Padua; 3Pediatric Headache Center, Department of Pediatric Emergency, Regina Margherita Children's Hospital, Turin; 4Children Epilepsy and EEG Center, San Paolo Hospital, ASL Bari; 5Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
267 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
129 -
OC-23 | The REPICEF Project: a school-based epidemiological study on primary headaches in children and adolescents Agnese Onofri,1 Chiara Rosignoli,1 Vittorio Trozzi,1 Martina D’Ambrosio,1 Benedetta Germani,1 Roberta Ciuffini,2 Raffaele Ornello,1 Simona Sacco1 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Clinical Medicine, Public health, Life and Environmental Sciences University of L’Aquila, Italy
89 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
230 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
242 -
PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy
237 -
OC-17 | Profiling miR-30a expression in patients with episodic and chronic migraine Elisa Rubino,1,2 Elisa Maria Piella,1 Giulia Cicilese,1,3 Silvia Boschi,1 Alberto Mario Chiarandon,1 Elena Tamagno,1,3 Michela Guglielmotto,1,3 Innocenzo Rainero1,2 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino; 3Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano (TO), Italy
119 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
179 -
PO-16 | Neurophysiological effects of atogepant in high-frequency episodic migraine B. Agostini,1,2 F. Cammarota,1,2 R. De Icco,1,2 V. Grillo,1,2 G. Vaghi,1,2 F. Bighiani1,2, M. Corrado,2 A. Antoniazzi,1,2 M. Giraudo,1,2 A. Solfrizzi,1,2 R. Greco,2 C. Demartini,1,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
205 -
PO-55 | What patients want: a qualitative study on an information resource on migraine Matteo Castaldo,1 Zhiqi Liang,2 Gina Williams,2 Shayne Watson,2 Caitlyn Haynes,2 Zoe Diamond2 | 1Parma University; 2University of Queensland
134 -
PO-14 | Pain catastrophizing in chronic migraine patients receiving eptinezumab treatment Alessandra Parisi,1 Licia Grazzi,1 Alberto Raggi,2 Giulia Regonesi,1 Montisano Danilo Antonio1 | 1Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano; 2Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy
256 -
PO-70 | A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score Marina Romozzi,1 Ammar Lokhandwala,2 Catello Vollono,1 David García-Azorín,3 Giulia Vigani,4 Francesco De Cesaris,4 Claudia Altamura,5 Fabrizio Vernieri,5 Paolo Calabresi,1 Sonia Di Tella,6 Luigi Francesco Iannone7 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Drexel University, Philadelphia, PA, USA; 3Hospital Universitario del Río Hortega, Valladolid, Headache Unit, Department of Neurology, Valladolid, Spain; 4Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy; 5 Neurologia, Dipartimento di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy; 6Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
193 -
PO-41 | Eptinezumab for difficult-to-treat migraine: who responds and who needs more Alessandro Visentini,1,2,3 Roberta Messina,1,2,3 Ilaria Cetta,1,2,3 Edorardo Ratto,1 Laura Zanandrea,1,3 Federica Genovese,1,2,3 Irene Chinali,1 Bruno Colombo,1 Massimo Filippi1,2,3 | 1Neurology Unit and 2Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; 3Vita-Salute San Raffaele University, Milan, Italy
231 -
OC-04 | The chronopharmacology of atogepant in migraine prevention: a real-world evaluation of influence of timing of administration on effectiveness and tolerability Luigi Francesco Iannone,1,2 Gabriele Sebastianelli,3 Flavia Lo Castro,2 Federico De Santis,4 Michele Corrado,5 Marilena Marcosano,6,7 Raffaele Ornello,4 Licia Grazzi,8 Danilo Antonio Montisano,8 Francesco De Cesaris,9 Antonio Munafò,9 Gianluca Avino,10 Michele Trimboli,11 Maria Albanese,12 Antonio Russo,13 Giorgio Dalla Volta,14 Marina Romozzi,15 Paola Merlo,16 Luisa Fofi,6,7 Alberto Doretti,17 Gloria Vaghi,5 Francesca Pistoia,4 Delfina Ferrandi,18 Stefania Battistini,19 Gianluca Coppola,3 Simona Sacco,4 Simona Guerzoni,2 Claudia Altamura,6,7 Fabrizio Vernieri,6,7 On behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia; 2Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 5Department of Brain and Behavioral Sciences, University of Pavia; Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 6Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 7Neurology Unit, Università Campus Bio-Medico di Roma; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache center and Clinical Pharmacology, AOU Careggi, Florence; 10SOC Neurologia, Ospedale di Prato; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 12Università Roma Tor Vergata, Roma; 13Università della Campania "Luigi Vanvitelli", Napoli; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo; 17Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano; 18Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy
145 -
PO-50 | Enhanced integration and synergy in EEG- and fNIRS-based networks in migraine patients following three-month galcanezumab treatment: associations with long-term clinical effects Giulia Paparella,1,2 Marianna La Rocca,3 Livio Clemente,1 Emmanuella Ladisa,1 Chiara Abbatantuono,1 Elena Ammendola,1 Marianna Diletta Delussi,4 Katia Ricci,1 Giusy Tancredi,1 Antonio Lacalamita,3 Alfonso Monaco,3 Nicola Amoroso,5 Sebastiano Stramaglia,3 Roberto Bellotti,3 Marina de Tommaso1 | 1Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Bari, Italy; 2IRCCS Neuromed, Pozzilli (IS), Italy; 3Interateneo Department of Physics "M. Merlin", University of Bari Aldo Moro, Bari, Italy; 4Department of Education, Psychology, Communication (For.Psi.Com.), University of Bari Aldo Moro, Bari, Italy; 5Department of Pharmacy–Drug Sciences, University of Bari Aldo Moro, Bari, Italy
118 -
PO-67 | Investigating plasma neurofilament light chain levels in patients with migraine: a cross-sectional study Elisa Maria Piella,1 Alberto Mario Chiarandon,1 Silvia Boschi,1 Fausto Roveta,1 Lucrezia Bonino,1 Giulia Gioiello,2 Giulia Montesano,2 Giulio Mengozzi,2 Innocenzo Rainero,1,3 Elisa Rubino1,3 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Clinical Biochemistry Laboratory “Baldi e Riberi”, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy; 3Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino, Turin, Italy
146 -
PO-39 | Leeds Dependence Questionnaire (LDQ) in migraine: diagnostic utility without predictive value for anti-CGRP (R) response Antonio Munafò,1 Andrea Burgalassi,1 Giulia Vigani,2 Francesco De Cesaris,1 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
216 -
PO-05 | Validation of the Italian version of the HARDSHIP Questionnaire in a school-based population Agnese Onofri,1 Chiara Rosignoli,1 Vittorio Trozzi,1 Martina D’Ambrosio,1 Benedetta Germani,1 Roberta Ciuffini,2 Raffaele Ornello,1 Simona Sacco1 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Clinical Medicine, Public health, Life and Environmental Sciences, University of L’Aquila, Italy
224 -
PO-63 | Acceptance and commitment therapy in the management of chronic headache pain E. Principe,1 M. Pirrotta,1 N. Fava,2 C. Marchio,1 L. M. Catalano,1 D. Bosco,2 R. Iannacchero,2 Alcmeone group | 1SPDC ASP Catanzaro, 2Centro Cefalee AOU R. Dulbecco Catanzaro, Italy
221 -
PO-61 | Social cognition in interictal episodic and chronic migraine: a cross-sectional study Chiara Abbatantuono,1* Delussi Marianna,2* Clemente Livio,1 Giulia Paparella,1 Stefania Scannicchio,1 Annalisa Di Dio,1 Elena Ammendola,1 Giusy Tancredi,1 Emmanuella Ladisa,1 Giulia Paparella,1,3 Marina de Tommaso1 (*Equally Contributed) | 1Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro (IT), Bari, Italy; 2Department of Education, Psychology, Communication (For.Psi.Com.), University of Bari Aldo Moro (IT), Bari, Italy; 3IRCCS Neuromed Pozzilli (IS), Italy
117 -
PO-24 | Inflammatory signatures of comorbid episodic migraine and endometriosis: a cytokine-based analysis Maria Albanese,1,2 Veronica Ceci,3,4 Giulia Carrera,4,5 Aikaterini Selntigia,6 Caterina Exacoustos,6 Marta Tiberi,4 Stefano Saracini,3,4 Alessandro Matteocci,4,7 Nicola Biagio Mercuri,1,2,8 Valerio Chiurchiù3,4 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome; 3Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome; 4Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, Rome; 5PhD Program in Neuroscience, Department of Systems Medicine, University of Rome Tor Vergata, Rome; 6Department of Surgical Sciences, Gynecological Unit, University of Rome Tor Vergata, Rome; 7PhD program in Immunology, Molecular Medicine and Applied biotechnologies, University of Rome Tor Vergata, Rome; 9Laboratory of Experimental Neuroscience, IRCCS Santa Lucia Foundation, Rome, Italy
187 -
PO-88 | Can tamoxifen and metformin nullify efficacy of CGRP-mAbs migraine prophylaxis? Patrizia Rossi,1,2 Valentina Cima,2 Alessandro Burlina2 | 1Headache Center, 2Neurology Department, San Bassiano Hospital, Bassano del Grappa (VI), Italy
421
1 - 39 of 39 items